Cancer remains one of the most formidable challenges to global healthcare. Driven by demographic shifts and mounting risk factors, its incidence continues to rise. Thankfully, diagnostic technologies are making strides—allowing for earlier detection and more precise intervention. The 2025 COMPAMED Innovation Forum, hosted by IVAM Microtechnology Network, spotlighted these breakthroughs, focusing on the future of medical diagnostics—and how COMPAMED will serve as a platform for turning innovation into impact.
This forum emphasized the transformative potential of medical technology in cancer detection—from novel biomarkers and microfluidic innovations to powerful photonics. Attendees gained insight into the trends shaping tomorrow’s diagnostics landscape.
Complementing the forum, COMPAMED 2025—Europe’s premier trade fair for medical technology suppliers—will run from November 17–20 in Halls 8a and 8b at Düsseldorf Exhibition Centre. Featuring over 750 exhibitors and held alongside the MEDICA trade fair, the event showcases the full spectrum of components, materials, and services shaping the future of MedTech.
The forum underscored the urgency and opportunity in advancing diagnostic tools—including:
- An upward trend in global cancer burden, with lung, breast, bowel, and prostate cancers among the most prevalent.
- A heightened incidence of lung and liver cancers linked to lifestyle factors (e.g., tobacco, poor nutrition, alcohol), environmental toxins, chronic infections (e.g., Hepatitis B/C, HPV), plus genetic predispositions and aging.
As medical diagnostics evolve, these innovations promise to enhance early detection, improve personalization, and ultimately, save lives. The COMPAMED Innovation Forum’s insights and connections, together with the wider exhibition at COMPAMED 2025, offer fertile ground for collaboration and commercialization in MedTech.
Credit from the press release
